Our evidence suggests that APE2 regulates the ATR DDR pathway in pancreatic cancer cells and that targeting the novel function of APE2 in ATR DDR may open a new avenue for future therapeutics in pancreatic cancers. This evidence concerns the gene APEX2 and familial pancreatic carcinoma.